A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms LUCY
- Sponsors AstraZeneca
- 23 Feb 2018 Planned End Date changed from 30 Jun 2020 to 29 Nov 2020.
- 23 Feb 2018 Planned primary completion date changed from 30 Jun 2020 to 29 Nov 2020.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.